Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID) Stock Price, Analysis & Data
| Bid | 2.11 |
| Market Cap | 561.48M |
| Revenue (ttm) | 1.58M |
| Net Income (ttm) | -34.48M |
| Beta | 0.23 |
| EPS (ttm) | -0.21 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.29 |
| P/B (ttm) | 2.53 |
| P/S (ttm) | 354.69 |
| Earnings Date | Nov 11, 2026 |
| Ask | 3.71 |
| Volume | 590,993 |
| Avg. Volume (20D) | 2,273,125 |
| Open | 2.90 |
| Previous Close | 2.84 |
| Day's Range | 2.87 - 2.94 |
| 52-Week Range | 0.89 - 3.10 |
| Analyst | Strong Buy |
| Price Target | 5 (71.82%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activa...
Financial Performance
In 2025, Ovid Therapeutics's revenue was 7.25M, an increase of 1,181.27% compared to the previous year's 566K. Earnings were -17.41M, a decrease of -34.12%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for OVID stock is "Strong Buy". The 12-month stock price forecast is 5, which is upside of 71.82% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
